Home | Life Sciences Intellectual Property Review
16 January 2025 A district court of appeal has paused MSN Pharmaceuticals’ launch | Result comes days after the Federal Circuit restored Novartis’ patent and overturned a decision in favour of MSN | Request is one in a flurry of filings between the pair over the heart-failure drug.
Latest News & Features | Life Sciences Intellectual Property Review
Jan 9, 2025 · Case concerns allegations that ex-senior vice president of business development at Skye Orthobiologics misappropriated secrets and breached contract | Companies in dispute process and manufacture medical products derived from human placental tissue.
ADCs, TCR, and multimodal AI: Transformative trends in 2025
16 hours ago · For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at [email protected]
Trump nixes Biden’s Executive Order on drug pricing
2 days ago · New president says repeal is first of “many steps the US federal government will take to repair our institutions and our economy” | Defunct order aimed to lower drug costs and place caps on essential medications | Big Pharma argues higher drug prices are necessary to fund R&D for new therapies.
Outlook for 2025: how Trump and the USPTO will affect life …
Jan 2, 2025 · Key developments for the industry this year include a more pro-patent administration and USPTO changes, say Carla Ji-Eun Kim and Deborah Sterling of Sterne Kessler.
Biotechnology | Life Sciences Intellectual Property Review
3 December 2024 German biotech asks federal judge to reject Amgen’s efforts to narrow scope of a key patent in ongoing dispute | Patent relates to Lindis' cancer immunotherapy treatment | Lindis calls on court to uphold the broader interpretation and claims Amgen’s attempt to narrow is inconsistent with the patent's history.
Americas | Life Sciences Intellectual Property Review
18 July 2024 Guidance says use of AI in inventing does not affect how patent claims are assessed for eligibility | Emphasis placed on evaluating inventions themselves rather than the method of creation | Updates include new examples to …
About | Life Sciences Intellectual Property Review
About. Life Sciences Intellectual Property Review tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences.From gene patents to stem cell research, we hope to provide the best news and analysis. For information about Single Licence and Corporate Licence subscription options, please contact Adrian Tapping: [email protected] ...
‘This is a big problem’: The CRISPR controversy and the ‘mess’ at …
Sep 27, 2024 · A request by CRISPR scientists to withdraw their patents over allegations of mishandling by the EPO’s Boards of Appeals has thrust a ‘fundamentally unfair, uncertain system’ into sharp focus, finds Sarah Speight.
LSPN launches its first-ever US awards to celebrate life sciences ...
Dec 17, 2024 · LSIPR’s key event series to host its inaugural ceremony next year in Boston | Spotlight on top innovators and firms in life sciences IP | Gala to honour contributions across 21 categories with 15 judges.